Ipsen and Sutro Biopharma announce exclusive global
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of...
Source: globenewswire.com
Page 2 - Amy Wolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Amy Wolf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Amy Wolf Today - Breaking & Trending Today
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a...
Source: marketscreener.com
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Total-sales growth in FY 2023 of 6.7% at CER1 included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% , based on further...
Source: marketscreener.com
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
PARIS, FRANCE, 7 December 2023 - Ipsen , a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our...
Source: marketscreener.com
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam
Source: yahoo.com